Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

NCT04475107 is registered in ClinicalTrials.gov with Shin Poong Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT04475107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04475107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 9, 2020
Completion date
April 15, 2021
Enrollment
113 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19